CRPS sometimes occurs comorbidly in those with EDS, and often “spreads” through the body. The pain can be debilitating and crippling, caused by intense burning, pins and needles and other nerve or”shock” like pain.
CRPS is also known as RSD and is considered “Neuro-Inflammatory Disorder” – a condition that involves dysfunction of the nervous system and the immune system. It’s described as a condition that “occurs when the nervous system and the immune system malfunction as they respond to tissue damage from trauma. The nerves misfire, sending constant pain signals to the brain. The level of pain is measured as one of the most severe on the McGill University Pain Scale. CRPS generally follows a musculoskeletal injury, a nerve injury, surgery or immobilization.” (source – http://rsds.org/telltale-signs-and-symptoms-of-crpsrsd/)
The International Pain Foundation is a great resource for chronic pain conditions, such as CRPS/RSD.
‘FDA Designates CRPS Drug as ‘Breakthrough Therapy.’
“The U.S. Food and Drug Administration has designated an experimental drug as a potential breakthrough therapy for Complex Regional Pain Syndrome (CRPS), a chronic and disabling neurological disease for which there is no cure or treatment.
Neridronic acid was discovered by Abiogen Pharma, an Italian drug maker, and is jointly being developed with Grünenthal, a German pharmaceutical company.
The Breakthrough Therapy designation by the FDA came after the companies reported the results of a Phase II clinical trial showing a significant reduction in pain and symptoms of CRPS with neridronic acid treatment. The drug has already received fast track and orphan drug designations from the FDA.
The agency considers a new drug as a breakthrough therapy if it is intended to treat a serious condition and if preliminary clinical evidence demonstrates substantial improvement over current treatments. There are no current FDA approved treatments for CRPS, which is also known as Reflex Sympathetic Dystrophy (RSD).”
The article quoted above was originally posted on Pain News Network.
Link to original article – https://www.painnewsnetwork.org/stories/2016/12/16/fda-designates-crps-drug-as-breakthrough-therapy